Supreme Court Appears Dubious Of Gene Patents, But Wary Of Halting Innovation
This article was originally published in The Gray Sheet
Executive Summary
Justices appeared to favor the government’s position that synthesized genetic material, but not isolated DNA, can be eligible for a patent during oral arguments last week in the case of The Association of Molecular Pathology v. Myriad Genetics Inc.